Introduction {#Sec1}
============

Since the 1970s, hydroxyethyl starch (HES) has been widely used for volume expansion therapy. A cross-sectional study reported that about 37.1% patients in the ICU received daily plasma volume expansion, mostly using HES \[[@CR1]\]. Another study showed that rapid intravenous infusion of HES increases cardiac output and expands blood volume more effectively than crystalloids \[[@CR2]\]. Numerous reviews without meta-analyses also support the clinical application of HES \[[@CR3],[@CR4]\].

However, the safety of HES for plasma volume expansion is still under research, especially as many studies by Boldt have been retracted due to scientific misconduct. Recently, three large-sample randomized controlled trials (RCTs) \[[@CR5]-[@CR7]\] and meta-analyses \[[@CR8]-[@CR10]\] have indicated that HES increases the need for renal replacement therapy (RRT) in critically ill patients and mortality in sepsis patients. The statement issued by the European Society of Intensive Care Medicine (ESICM) recommends that products containing HES should not be used in septic patients (1B), other intensive care patients at a high risk of acute kidney injury (AKI) (1C) or patients with head injury or intracranial bleeding (1C) \[[@CR11]\]. However, another international multi-center large-sample RCT reported the use of colloids (including HES, gelatin, dextran and albumin) versus any crystalloids for volume expansion therapy to decrease 90-day mortality without increasing the need for in ICU patients \[[@CR12]\]. Hence, we wanted to further study the effect of the use of HES in ICU patients.

There are also many non-septic patients in the ICU who require volume expansion therapy, such as those with acute hypovolemia arising from trauma, bleeding or surgery. So far, there is a lack of effective and comprehensive evidence-based trials focusing on the safety of HES for non-septic patients in the ICU. However, Zarychanski *et al*. \[[@CR8]\] have reported on the use of HES in critically ill patients, and performed subgroup analyses to compare trials of septic versus non-septic patients in their meta-analysis, the results were inconsistent between subgroups. After exclusion of the Boldt' papers HES was shown to significantly increase the risk of mortality in all critically ill patients. However, HES did not increase the mortality in the non-septic subgroup, which was contradictory to the result obtained from the septic subgroup in their paper. Furthermore, subgroup analysis was performed only for mortality; AKI and RRT incidence were not reported in the non-septic subgroup. Mutter *et al*. \[[@CR9]\] made a systematic review to assess the effects of HES versus other fluids on kidney function in all patient populations. HES products were found to increase the risk in AKI and RRT in all patients. Surprisingly, Mutter *et al*. detected a significant decrease in risk and injury of renal function according to the risk, injury, failure, loss of kidney function and end-stage kidney disease (RIFLE) criteria in the non-septic subgroup treated with HES versus other fluids \[[@CR9]\].

Two meta-analyses published recently demonstrated that use of HES for volume expansion therapy during surgery was not associated with increased postoperative mortality or RRT use \[[@CR13],[@CR14]\], which differed from the studies focusing on septic patients. However, Cittanova *et al*. reported that HES significantly increases serum creatinine concentrations during the first 8 days after transplantation in kidney-transplant recipients \[[@CR15]\]. These results suggest that HES could have different effects on different diseases. Therefore, whether or not use of HES in non-septic ICU patients could induce a result similar to that seen in septic ICU patients needs to be further confirmed. The aim of the present study was to evaluate the impact of 6% HES on mortality, RRT use, bleeding volume, red blood cell (RBC) transfusion and fluid application among non-septic patients in the ICU.

Materials and methods {#Sec2}
=====================

According to the methodology recommended by the Cochrane Collaboration \[[@CR16]\], we included related RCTs for analyzing the safety of 6% HES for non-septic patients in the ICU. The primary endpoints were overall mortality and use of RRT, and the secondary endpoints were bleeding volume, RBC transfusion and fluid application. We reported the meta-analysis according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) criteria \[[@CR17]\].

Studies were selected if they met the following criteria: 1) RCTs; 2) patient age ≥18 years; 3) studies consisting of a group of patients in whom 6% HES was used, and a control group receiving other intravenous fluids in the ICU; and 4) subgroups of non-septic patients who were reported to have received 6% HES and other intravenous fluids in the ICU. Studies were excluded if they had any of the following characteristics: 1) septic patients as research subjects; 2) no group receiving 6% HES; 3) no data available and 4) Boldt's research studies.

Search strategy {#Sec3}
---------------

We searched Pubmed, OvidSP, Embase database and the Cochrane Library, including reference lists of relevant clinical trials, systematic reviews and meta-analyses published before November 2013, and that met the above criteria. The term in MeSH was "Hetastarch" and related free words were also searched such as "hydroxyethylstarch", "HES", "Tetraspan", "Voluven" and so on. The search was limited by "RCTs", "human" and "adult". "Language" was not a restricted searching condition. Details are provided in Additional file [1](#MOESM1){ref-type="media"}.

Data extraction {#Sec4}
---------------

Two reviewers (BH, BX) independently screened the results of the retrieved and acquired full texts that met the above criteria. For each acquired article, the two reviewers independently extracted the valid data, including overall mortality, RRT use, bleeding volume, RBC transfusion, and fluid application during the first day in ICU. A third reviewer (XX) would arbitrate in the event of any disagreement between the two reviewers.

Risk of bias assessment and study quality {#Sec5}
-----------------------------------------

The Cochrane Collaboration risk-of-bias tool \[[@CR16]\] was used to evaluate the internal validity of the included articles. The tool contained the following items: generation of random sequence, allocation concealment, blinding, incomplete data reporting, selective reporting results and other problems that could put the study at a risk of bias. Quality assessment was evaluated using mthe odified Jadad score \[[@CR18]\]. The scale is a score from 0 to 7 (highest level of quality) according to generation of random sequence, allocation concealment, blinding, and withdrawals of clinical trials. High quality was defined by a Jadad score of 4 to 7; low quality was defined by a Jadad score ≤3.

Statistical analysis {#Sec6}
--------------------

Review Manager (RevMan, version 5.2) was used to analyze the included studies and data. Standard mean difference (SMD) was used for pooling continuous data. When median and extreme values were presented in the original articles, these data were converted into mean and SD according to relevant formulas \[[@CR19]\]. If median and quartile range were reported, mean value and SD were estimated by the method provided in the 7.7.3.5 section of the Cochrane Handbook \[[@CR16]\]. If the HES groups or control groups included more than one group, the respective data were pooled (weighted estimate) according to the Cochrane Handbook (7.7.3.8 section) \[[@CR16]\]. For non-continuous data, relative risk (RR) was adopted. Heterogeneity was quantified using the *I*^2^-test \[[@CR20]\]. The fixed effects model was selected if there was no heterogeneity (*I*^2^ \< 50%), and the random effects model was selected in the event of 50% ≤ *I*^2^ \< 75%. A sensitivity analysis or subgroup analysis was performed to exclude the heterogeneity if *I*^2^ was ≥75%, otherwise meta-analysis was not carried out. Publication bias was tested using funnel plots and the Egger's test \[[@CR21]\]. Two-sided tests were performed with a significant difference at *P* \<0.05.

Results {#Sec7}
=======

RCTs included {#Sec8}
-------------

The flow diagram of this meta-analysis is presented in Figure [1](#Fig1){ref-type="fig"}. A total of 2,919 articles were retrieved, of which 2,897 were excluded. Finally, 22 eligible RCTs were included in this meta-analysis according to the inclusion and exclusion criteria.Figure 1**Flow diagram of this meta-analysis.**

Characteristics of the included studies and study quality {#Sec9}
---------------------------------------------------------

The characteristics of the 22 included RCTs are shown in Table [1](#Tab1){ref-type="table"}. Of these, 14 RCTs reported patients who had undergone complex surgical procedures needing volume expansion therapy in the ICU \[[@CR22]-[@CR35]\], and 8 RCTs reported patients with other diseases (such as cardiac arrest, trauma, and so on) who received volume expansion therapy in the ICU \[[@CR6],[@CR36]-[@CR42]\]. Two RCTs reported data for a non-septic subgroup \[[@CR6],[@CR38]\], and we included these data. These studies used different indicators to evaluate whether patients reached circulation stabilization. For example, one study used cardiac index \[[@CR22]\], some chose urine and central venous pressure \[[@CR37],[@CR41],[@CR42]\], and others combined several indicators \[[@CR23],[@CR24],[@CR28]-[@CR32],[@CR39]\].Table 1**Characteristics of articles included, patient diagnosis, number of participants, interventions, and related details of reportsAuthor, yearDiagnosisPatients (n)InterventionControlTotal dose of hydroxyethyl starch** **(HES)Volume expansion goalsIntervention periodPD or CAStudy fluidsn1Control fluids n2**Ley, 1990 \[[@CR22]\]After cardiac surgery216% HES 450/0.7 11Normal saline10Up to 1.5 LCI \>2.0 L/min/m^2^NSPDBeards,1994 \[[@CR36]\]Hypovolemia256% HES 450/0.7 13Gelatin12500 mL bolusNS15 to 30 minutesPDVan der Linden, 2005 \[[@CR23]\]After cardiac surgery1326% HES 130/0.464Gelatin68Maximum 50 mL/kg/dayPAOP, 8 to 15 mmHgNSPDCI \>2.5 L/min/m^2^Urine \>0.5 mL/kg/hChen, 2006 \[[@CR37]\]Burn666% HES 130/0.433Plasma332328 ± 271 mLCVP 7 to 14 mmHg48 hCAUrine \>0.5 mL/kg/hMahmood, 2007 \[[@CR24]\]After aortic aneurysm surgery626% HES 130/0.421Gelatin20Surgery, 3 ml/kg/hMAP \>85 mmHgSurgery and ICUPD6% HES 200/0.6221CU, as neededCVP 8 to 10 mmHgGodet, 2008 \[[@CR25]\]After abdominal aortic surgery656% HES 130/0.432Gelatin33As neededDoctor's judgementSurgery and 6 d in ICUPDMukhtar, 2009 \[[@CR26]\]After transplantation surgery406% HES 130/0.420Albumin20Maximum 50 mL/kg/dayCVP, 5 to 7 mmHgSurgery and 4 d in ICUPDOoi, 2009 \[[@CR27]\]After cardiac surgery906% HES 130/0.445Gelatin45As neededCVP, 10 to 14 mmHgNSPDSchramko, 2009 \[[@CR28]\]After cardiac surgery456% HES 130/0.415Albumin15NSPAWP, 10 to 14 mmHgNSPD6% HES 200/0.6215CI \>2.0 L/min/m^2^Choi, 2010 \[[@CR29]\]After abdominal aortic surgery366% HES 130/0.418Albumin18Maximum 20 mL/kg in ICUPAOP, 10 to 14 mmHgNSPDCI \>2.0 L/min/m^2^Urine \>0.5 mL/kg/hGondos, 2010 \[[@CR38]\]Hypovolemia1066% HES 130/0.426RL2810 mL/kgNSNSPDGelatin25Albumin27Heradstveit, 2010 \[[@CR39]\]After cardiac arrest196% HES 200/0.510RL9maximum 500 mL/24 hMAP \>60 mmHgObservation periodPDHR, 60 to 100/minCVP, 8 to 12 mmHgInal, 2010 \[[@CR40]\]Hypovolemia306% HES 130/0.415Gelatin15500 mLNSNSPDSchramko, 2010 \[[@CR30]\]After cardiac surgery456% HES 130/0.415RL1528 mL/kgPCWP, 10 to15 mmHg16 to 20 h in ICUPDGelatin15CI \> 2.0 L/min/m^2^Du, 2011 \[[@CR41]\]Acute pancreatitis416% HES 130/0.420RL21as neededCVP, 8 to 15 mmHg8 d in hospitalCA1:3 with salineUrine \>0.5 mL/kg/hSBP \>90 mmHgJames, 2011 \[[@CR42]\]Trauma1096% HES 130/0.456Normal saline53500 mL bolusesCVP \>12 mmHg15 minutesPDUrine \>0.5 mL/kg/hLee, 2011 \[[@CR31]\]After cardiac surgery1066% HES 130/0.453Crystalloid53Maximum 50 mL/kg/dCI \>2.2 L/min/m^2^NSPDSvO2 \> 60%Urine \>0.5 mL/kg/hYang, 2011 \[[@CR32]\]After hepatectomy816% HES 130/0.426RL251,000 mL/d\*3dCVP, 5 to 9 mmHg5 dCAAlbumin30500 mL/d\*2dMAP, 60 to 80 mmHgMyburgh, 2012 \[[@CR6]\]Non-septic patients47206% HES 130/0.42337Normal saline2383500 mL bolus, maximum 50 mL/kg/dNS90 dCAAlavi, 2012 \[[@CR33]\]After cardiac surgery926% HES 130/0.432RL29As neededCVP, 7 to 14 mmHgSurgery and ICUPDGelatin31Nagpal D, 2012 \[[@CR34]\]After cardiac surgery706% HES 130/0.435Crystalloid351 to 3.0 L/dNSNSPDKimenai, 2013 \[[@CR35]\]After cardiac surgery606% HES 130/0.430Gelatin30NSNSNSPDRL, Ringer lactate; n, number of overall patients; n1, number of patients in intervention group; n2 number of patients in control group; NS, not stated; CI, cardiac index; PAOP, pulmonary artery occlusive pressure; CVP, central venous pressure; MAP, mean arterial pressure; PAWP, pulmonary artery wedge pressure; HR, heart rate; PCWP, pulmonary capillary wedge pressure; SBP systolic blood pressure; SvO2, mixed venous oxygen saturation; PD, published data; CA, connected with author successfully.

Among our included articles, 14 RCTs \[[@CR6],[@CR23]-[@CR27],[@CR32],[@CR34],[@CR36],[@CR38]-[@CR42]\] reported the overall mortality; 9 RCTs \[[@CR24]-[@CR27],[@CR31],[@CR34],[@CR37],[@CR41],[@CR42]\] reported the incidence of RRT; 10 RCTs \[[@CR22]-[@CR24],[@CR27]-[@CR31],[@CR33],[@CR35]\] reported bleeding volume after surgery; 10 RCTs \[[@CR22],[@CR24]-[@CR28],[@CR30],[@CR31],[@CR33],[@CR35]\] reported RBC transfusion after surgery; and 9 RCTs \[[@CR23],[@CR27]-[@CR30],[@CR32],[@CR33],[@CR37],[@CR42]\] reported fluid application during the first day in ICU (Additional file [2](#MOESM2){ref-type="media"}: Table S1). According to the modified Jadad score, high quality was determined in 13 studies, and low quality was determined in 9 studies (Table [2](#Tab2){ref-type="table"}).Table 2**Risk of bias and literature qualityTrialsRandom sequence generationAllocation concealmentBlindingIncomplete outcome data treatmentSelective outcome reportingOther biasJadad score**High QualityVan der Linden, 2005 \[[@CR23]\]LowUnclearHighLowLowLow4Mahmood, 2007 \[[@CR24]\]LowLowHighLowLowLow5Godet, 2008 \[[@CR25]\]LowLowHighLowLowHigh4Mukhtar, 2009 \[[@CR26]\]UnclearLowUnclearLowLowUnclear4Schramko, 2009 \[[@CR28]\]UnclearLowUnclearLowLowLow4Gondos, 2010 \[[@CR38]\]UnclearLowUnclearLowLowLow4Schramko, 2010 \[[@CR30]\]UnclearLowHighLowLowLow4Du, 2011 \[[@CR41]\]LowUnclearUnclearHighHighLow4James, 2011 \[[@CR42]\]LowLowLowHighLowLow6Myburgh, 2012 \[[@CR6]\]LowLowLowLowLowLow7Alavi, 2012 \[[@CR33]\]UnclearLowLowLowLowLow4Nagpal, 2012 \[[@CR34]\]LowLowLowUnclearLowLow5Kimenai, 2013 \[[@CR35]\]LowUnclearHighLowLowLow4Low QualityLey, 1990 \[[@CR22]\]UnclearUnclearUnclearLowLowUnclear2Berard, 1994 \[[@CR36]\]UnclearUnclearUnclearLowLowLow2Chen, 2006 \[[@CR37]\]LowUnclearHighLowLowUnclear3Ooi, 2009 \[[@CR27]\]UnclearUnclearHighLowUnclearLow2Choi, 2010 \[[@CR29]\]LowUnclearUnclearLowLowLow3Heradstveit, 2010 \[[@CR39]\]UnclearUnclearHighLowLowHigh2Inal, 2010 \[[@CR40]\]UnclearUnclearUnclearLowUnclearLow2Lee, 2011 \[[@CR31]\]UnclearUnclearHighLowLowLow2Yang, 2011 \[[@CR32]\]LowUnclearUnclearHighLowLow3

Overall mortality {#Sec10}
-----------------

A total of 14 articles reported the overall mortality, involving 5,593 patients. Compared with the other types of fluids (crystalloids, gelatine or albumin), the use of 6% HES was not associated with decreased overall mortality (RR = 1.03, 95% CI 0.90 to 1.17; *P* = 0.67; *I*^2^ = 0) (Figure [2](#Fig2){ref-type="fig"}). Publication bias was not found by the Egger's test (*P* = 0.85) or funnel plots (Figure [3](#Fig3){ref-type="fig"}).Figure 2**Forest plot of pooled risk ratio for overall mortality.** HES, hydroxethyl starch. M-H, Mantel-Haenszel.Figure 3**Funnel plot of overall mortality.** RR, relative risk. SE, standard error.

Renal replacement therapy {#Sec11}
-------------------------

Nine articles reported the incidence of RRT, showing that 6% HES did not increase RRT use as compared with the other fluids (RR = 0.83; 95% CI 0.36 to 1.91; *P* = 0.67; *I*^2^ = 0%) (Figure [4](#Fig4){ref-type="fig"}). Funnel plots showed no publication bias (Figure [5](#Fig5){ref-type="fig"}), and the *P*-value from Egger's test was 0.58.Figure 4**Forest plot of pooled risk ratio for use of renal replacement therapy.** HES, hydroxethyl starch. M-H, Mantel-Haenszel.Figure 5**Funnel plot of incidence for renal replacement therapy.** RR, relative risk. SE, standard error.

Bleeding volume and RBC transfusion {#Sec12}
-----------------------------------

Bleeding volume was reported in 10 articles. Of these, we only pooled seven articles \[[@CR22],[@CR27],[@CR28],[@CR30],[@CR31],[@CR33],[@CR35]\] in this meta-analysis, which all reported bleeding volume after surgery. Three articles \[[@CR23],[@CR24],[@CR29]\] were excluded, as bleeding volume was reported from surgery or during several periods after surgery. Data from Schramko *et al*., Alavi *et al*. and Kimenai *et al*. were converted into mean and SD according to the method above \[[@CR16],[@CR19]\]. There was no significant difference in bleeding volume between the 6% HES group and other fluid groups (SMD = −0.10, 95% CI −0.29 to 0.08; *P* = 0.28; *I*^2^ = 0%) (Figure [6](#Fig6){ref-type="fig"}A). Egger's test showed no publication bias (*P* = 0.35).Figure 6**Forest plots of pooled estimates for bleeding volume and red blood cell transfusion. (A)** Bleeding volume after surgery. **(B)** Red blood cell transfusion (unit). HES, hydroxethyl starch. IV, Inverse Variance.

Nine articles reported RBC transfusion, and five articles \[[@CR22],[@CR23],[@CR26],[@CR31],[@CR42]\] reporting RBC transfusion after surgery were included and showed no significant difference between the HES group and other fluids group (SMD = −0.13; 95% CI −0.33 to 0.08; *P* = 0.23; *I*^2^ = 4%) (Figure [6](#Fig6){ref-type="fig"}B). Egger's test showed no publication bias (*P* = 0.51). Four articles were excluded because two of them \[[@CR28],[@CR33]\] only reported overall volume of RBC transfusion, and the other two \[[@CR24],[@CR26]\] reported RBC transfusion before surgery. Data from three articles were transformed \[[@CR23],[@CR26],[@CR42]\].

Fluid application {#Sec13}
-----------------

Fluid application during the first day in ICU was reported in nine articles, but there was significant data heterogeneity (*I*^2^ = 94%). Knowing that colloids and crystalloids have different effects on volume expansion, a subgroup analysis was performed by the type of fluid used. Patients receiving 6% HES needed fewer total intravenous fluids than those receiving crystalloids (SMD = −0.84, 95% CI −1.39 to −0.30; *P* = 0.003; *I*^2^ = 74%) (Figure [7](#Fig7){ref-type="fig"}A). There was no significant difference between the 6% HES group and albumin group (SMD = 0.26, 95% CI −0.17 to 0.70; *P* = 0.23; *I*^2^ = 13%) (Figure [7](#Fig7){ref-type="fig"}C). In this subgroup, data from Choi *et al*. \[[@CR29]\] were excluded, because they were reported in several periods during the first day in ICU, and we failed to obtain the data from the authors. Although subgroup analysis was carried out, there remained great heterogeneity in the fluid application between the HES group and the gelatin group. A sensitivity analysis identified that the trial from Alavi *et al*. \[[@CR33]\] was responsible for the heterogeneity. When their data were excluded, there was no significant difference in fluid application between the HES group and the gelatin group (SMD = −0.12, 95% CI −0.37 to 0.13; *P* = 0.35; *I*^2^ = 0%) (Figure [7](#Fig7){ref-type="fig"}B).Figure 7**Forest plots of pooled estimates for fluid application (mL) during the first day in the ICU. (A)** Hydroxethyl starch (HES) versus crystalloid. **(B)** HES versus gelatin. **(C)** HES versus albumin. IV, Inverse Variance.

Length of ICU and hospital stay {#Sec14}
-------------------------------

Eleven articles reported the length of ICU stay, and nine articles reported the length of hospital stay. However, significant heterogeneity was detected in both (ICU stay: *I*^2^ = 85%; hospital stay: *I*^2^ = 78%). As the heterogeneity could not be excluded through subgroup analysis or sensitivity analysis, a description was provided instead of performing a meta-analysis. These data are not shown.

Discussion {#Sec15}
==========

The main finding of this meta-analysis showed that HES was not associated with decreased overall mortality and RRT use. These findings were similar with subgroup analyses of non-septic patients among critically ill patients or among all patients \[[@CR8],[@CR9]\]. Our results were somewhat different from a previous meta-analysis of fluid therapy in critically ill patients, especially septic patients \[[@CR43]\]. One major cause was that the existing data for these patients treated with HES was poor and scarce, which meant the results needed to be verified with more data of high quality. Another reason might also be that the pathophysiological changes in these non-septic patients are different from those in septic patients, and sepsis itself could significantly increase the risk of AKI \[[@CR44]\]. Micro leakage of capillary blood vessels was a key pathophysiologic mechanism in sepsis \[[@CR45]\], and endothelial glycocalix plays an important role in micro leakage of capillary blood vessels \[[@CR46]\]. Steppan *et al*. found that significantly more flaking of the endothelial glycocalix occurred in patients with sepsis than in patients who underwent major abdominal surgery \[[@CR47]\]. In addition, sepsis could activate the renin-angiotensin-aldosterone system (RAAS) in renal sympathetic and angiotensin activities, which leads to vasoconstriction in patients with sodium and water retention. As a result, septic patients are predisposed to acute renal failure \[[@CR44]\]. Hence, the side effects of HES might be more serious for septic patients than non-septic patients in the ICU.

Although several studies tried to analyze the effect of HES in a non-septic subgroup, the results of their subgroup analyses were always different from their main results \[[@CR8],[@CR9]\]. In addition, their analyses were always part of the side effects of HES. Hence, we have made a meta-analysis to study the effect HES versus other fluids for non-septic ICU patients, including mortality, RRT use, bleeding volume, RBC transfusion and fluid application. This analysis was relatively comprehensive and with less heterogenicity in non-septic patients. Furthermore, it reminded us to pay more attention to volume expansion therapy in ICU non-septic patients.

The pooled analysis of overall mortality did not display more harm with HES, which was not entirely the same as previous trials \[[@CR5]-[@CR7]\] and meta-analyses \[[@CR8],[@CR10],[@CR48],[@CR49]\]. Knowing that the pooled analysis of mortality may be influenced by study quality and the follow-up period, it is difficult to explain this result. On the one hand, HES may have different effects in different diseases \[[@CR5]-[@CR7],[@CR13],[@CR14]\]. On the other hand, study quality and the follow-up period may induce bias in our meta-analysis, as most included RCTs were small-sample studies and with short follow-up periods. Hence, we should be cautious when selecting fluids for ICU non-septic patients. In addition, the article from CHEST \[[@CR6]\] alone accounted for 88.9% of the weighting, and the results, which played an important role in our meta-analysis, might only be suitable for the specific clinical conditions in that study (for example, a small dose of HES was chosen). We have performed a sensitivity analysis, and its exclusion did not influence the significance of the effect on overall mortality (RR = 0.83, 95% CI 0.56 to 1.24; *P* = 0.37; *I*^2^ = 0). However, other included studies were all with very small-scale samples; more high-quality RCTs focusing on 6% HES in non-septic ICU patients are needed to confirm our results.

Efforts were also made to determine the effect of 6% HES on renal function. However different indicators were used to test renal function, such as blood creatinine \[[@CR32]\], glomerular filtration rate \[[@CR30]\], the incidence of AKI based on different criteria \[[@CR24],[@CR34],[@CR42]\] and RRT use \[[@CR24]-[@CR27],[@CR31],[@CR34],[@CR37],[@CR41],[@CR42]\]. The result need further confirmation because of the limitations of our included RCTs.

There was no significant difference in bleeding volume and RBC transfusion between the 6% HES group and the other fluid groups. Patients in the HES group received fewer total intravenous fluids than those receiving crystalloids during the first day in ICU, which might mean that 6% HES had a better volume-expansion effect than crystalloids. However, due to the absence of demonstrable benefit, more large-scale RCTs are needed to confirm these results.

The implementation of our meta-analysis is in accordance with the requirements of the Cochrane Collaboration. These requirements include a literature search without language limitations, strict inclusion and exclusion criteria, selection of articles and collection of data by two independent authors, and bias risk evaluation. Indeed, there are several limitations in our meta-analysis. Despite widespread use of HES for more than three decades, RCTs comparing HES with other fluids for ICU non-septic patients are few, with small sample sizes, and vulnerable to bias. In addition, several control groups in the included studies used gelatin, which clouds or conceals the adverse effects of HES to some extent. Bleeding volume analysis is limited by clinical heterogeneity across studies because patients have undergone different types of surgery.

Conclusion {#Sec16}
==========

Although volume expansion with 6% HES did not seem to increase the mortality or RRT use in non-septic ICU patients, the sample sizes in our meta-analysis were small and the studies generally were of poor quality.

Key messages {#Sec17}
============

The safety of HES for non-septic patients in the ICU remains elusiveAvailable data from systematic reviews and meta-analyses displayed inconsistent results between septic and non-septic patients using HESUse of 6% HES did not seem to increase the mortality or RRT incidence in non-septic ICU patients

Additional files {#Sec18}
================

Additional file 1:***A priori*** **design, electronic search strategy and studies excluded from this review.**Additional file 2: Table S1.Observation period for outcomes.
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